Logo

CTNM

Contineum Therapeutics, Inc. Class A Common Stock

CTNM

Contineum Therapeutics, Inc. Class A Common Stock • NASDAQ
$11.07 ▲ 2.88% (+0.31)
Market Cap $323.03 M
52w High $15.40
52w Low $3.35
Dividend Yield 0%
P/E -4.92
Volume 76.32K
Outstanding Shares 29.18M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $14.851M ▼ $-12.792M ▲ 0% $-0.45 ▲ $-12.711M ▲
Q2-2025 $0 $17.823M ▼ $-16.04M ▼ 0% $-0.62 $-15.961M ▲
Q1-2025 $0 $18.11M ▲ $-15.99M ▼ 0% $-0.62 ▲ $-18.032M ▼
Q4-2024 $0 $-84.741M ▼ $-14.565M ▼ 0% $-0.65 ▼ $-14.49M ▼
Q3-2024 $0 $12.974M $-10.267M 0% $-0.4 $-10.205M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $182.407M ▲ $190.847M ▲ $10.377M ▼ $180.47M ▲
Q2-2025 $175.484M ▼ $182.888M ▼ $11.498M ▼ $171.39M ▼
Q1-2025 $190.71M ▼ $198.264M ▼ $13.496M ▼ $184.768M ▼
Q4-2024 $204.76M ▼ $212.847M ▼ $14.781M ▲ $198.066M ▼
Q3-2024 $213.911M $216.034M $5.806M $210.228M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-12.792M ▲ $-12.197M ▲ $14.941M ▲ $19.105M ▲ $21.849M ▲ $-12.295M ▲
Q2-2025 $-16.04M ▼ $-15.661M ▼ $13.884M ▼ $91K ▲ $-1.686M ▼ $-15.705M ▼
Q1-2025 $-15.99M ▼ $-14.412M ▼ $14.915M ▲ $24K ▼ $527K ▲ $-14.459M ▼
Q4-2024 $-14.565M ▼ $-10.202M ▼ $-9.388M ▲ $642K ▲ $-18.948M ▲ $-10.368M ▼
Q3-2024 $-10.267M $-6.169M $-30.183M $13K $-36.339M $-6.251M

Five-Year Company Overview

Income Statement

Income Statement Contineum is still a research‑stage biotech, so it has essentially no recurring product revenue. The tiny bump in revenue and profit a year ago looks like a one‑off event, likely from a partnership payment, not a sustainable business line. Underlying operations remain loss‑making as the company spends on clinical trials and R&D. Losses have widened most recently, which is typical as programs move deeper into human studies, but it also means the business is heavily dependent on external funding until any drug is approved and commercialized.

Balance Sheet

Balance Sheet The balance sheet has strengthened meaningfully in the most recent year. Total assets and cash have stepped up, debt has dropped sharply, and shareholder equity has swung from negative to clearly positive. This pattern usually reflects a significant capital raise or IPO that cleaned up prior leverage and recapitalized the company. The structure now looks more resilient for a clinical‑stage biotech, though the asset base is still mostly cash and R&D‑related, not hard assets or established products.

Cash Flow

Cash Flow Cash flow reflects an early‑stage R&D company: money is going out to fund research, not coming in from products. Operating cash flow has usually been negative, with a brief positive year that likely tied to a milestone or upfront payment. There is essentially no spending on physical assets, so cash use is almost entirely driven by clinical and development costs. Future cash needs will depend on how quickly trials progress and whether the company can continue to tap capital markets or partners to replenish its cash balance.

Competitive Edge

Competitive Edge Contineum operates in a crowded but attractive niche: neurology, inflammation, and immunology, all areas with large unmet medical need. Its edge comes from focused expertise in oral small molecules, especially assets that can reach the brain or stay outside it by design, and from targeting well‑validated biological pathways. The partnership with Janssen provides external validation and access to big‑pharma capabilities, which can be a real help for a small company. On the other hand, Contineum is small, depends heavily on a few key programs, and competes against large pharmaceutical players with deeper pockets and broader pipelines.

Innovation and R&D

Innovation and R&D Innovation is the core of the Contineum story. The lead asset PIPE‑791, a brain‑penetrant LPA1 blocker, is designed to address both fibrotic and neuroinflammatory conditions with a convenient oral pill, which, if successful, would be a strong differentiator. The company is also building a franchise around the same target with a peripherally‑restricted follow‑on candidate, showing a clear, focused R&D strategy. The collaboration asset PIPE‑307 had a clinical setback in multiple sclerosis but still has potential in other neurological and psychiatric uses. Overall, the pipeline is scientifically interesting but still early and concentrated, so the success or failure of a small number of trials will have an outsized impact.

Summary

Contineum is a classic clinical‑stage biotech: very limited recurring revenue today, ongoing operating losses, and a strengthened but still funding‑dependent balance sheet. Recent capital raising has materially improved its financial footing, reducing debt and restoring positive equity, which gives more room to pursue its R&D plans. The investment case rests almost entirely on the scientific and clinical progress of a few key programs, particularly PIPE‑791, and on the ability to turn promising biology into clear, reproducible clinical benefit. This creates significant upside potential but also substantial uncertainty, with typical biotech risks around trial outcomes, regulatory decisions, competition, and future access to capital.

NEWS

November 24, 2025 · 4:05 PM UTC

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

Read more

November 20, 2025 · 4:05 PM UTC

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Read more

October 30, 2025 · 4:05 PM UTC

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Read more

September 18, 2025 · 8:05 AM UTC

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Read more